Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) – Equities researchers at B. Riley issued their Q2 2022 earnings per share (EPS) estimates for Viridian Therapeutics in a research report issued on Thursday, June 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($1.01) for the quarter. B. Riley currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.75) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2022 earnings at ($1.01) EPS, Q4 2022 earnings at ($1.05) EPS, FY2023 earnings at ($3.64) EPS, FY2024 earnings at ($3.21) EPS and FY2025 earnings at ($3.26) EPS.
Viridian Therapeutics (NASDAQ:VRDN – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.06). The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.65 million. Viridian Therapeutics had a negative return on equity of 360.68% and a negative net margin of 5,014.24%.
Separately, JMP Securities decreased their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, March 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.80.
Shares of NASDAQ:VRDN opened at $10.97 on Friday. The stock’s 50-day moving average price is $12.54 and its two-hundred day moving average price is $17.00. Viridian Therapeutics has a 12-month low of $9.47 and a 12-month high of $22.00. The firm has a market cap of $306.36 million, a price-to-earnings ratio of -1.90 and a beta of 1.13.
In other Viridian Therapeutics news, CEO Jonathan Violin sold 30,000 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $13.04, for a total transaction of $391,200.00. Following the sale, the chief executive officer now directly owns 510,905 shares in the company, valued at approximately $6,662,201.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 90,000 shares of company stock worth $1,324,836 over the last 90 days. 4.48% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. acquired a new position in Viridian Therapeutics during the 1st quarter valued at approximately $32,164,000. Deep Track Capital LP acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $26,426,000. TCG Crossover Management LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $25,978,000. Citadel Advisors LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $18,650,000. Finally, Perceptive Advisors LLC boosted its position in Viridian Therapeutics by 79.1% during the 3rd quarter. Perceptive Advisors LLC now owns 1,423,000 shares of the company’s stock valued at $23,408,000 after purchasing an additional 628,494 shares during the period.
About Viridian Therapeutics (Get Rating)
Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.
Receive News & Ratings for Viridian Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viridian Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.